340 related articles for article (PubMed ID: 16645620)
21. Effects of cepharanthine alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice.
Harada K; Ferdous T; Itashiki Y; Takii M; Mano T; Mori Y; Ueyama Y
Anticancer Res; 2009 Apr; 29(4):1263-70. PubMed ID: 19414373
[TBL] [Abstract][Full Text] [Related]
22. Oncolytic recombinant herpes simplex virus for treatment of orthotopic liver tumors in nude mice.
Chung YS; Miyatake S; Miyamoto A; Miyamoto Y; Dohi T; Tanigawa N
Int J Oncol; 2006 Apr; 28(4):793-8. PubMed ID: 16525626
[TBL] [Abstract][Full Text] [Related]
23. Antitumor activity of a selectively replication competent herpes simplex virus (HSV) with enzyme prodrug therapy.
Braidwood L; Dunn PD; Hardy S; Evans TR; Brown SM
Anticancer Res; 2009 Jun; 29(6):2159-66. PubMed ID: 19528476
[TBL] [Abstract][Full Text] [Related]
24. Potent systemic antitumor activity from an oncolytic herpes simplex virus of syncytial phenotype.
Fu X; Zhang X
Cancer Res; 2002 Apr; 62(8):2306-12. PubMed ID: 11956088
[TBL] [Abstract][Full Text] [Related]
25. MicroRNA regulation of oncolytic herpes simplex virus-1 for selective killing of prostate cancer cells.
Lee CY; Rennie PS; Jia WW
Clin Cancer Res; 2009 Aug; 15(16):5126-35. PubMed ID: 19671871
[TBL] [Abstract][Full Text] [Related]
26. Systemic delivery of (gamma1)34.5-deleted herpes simplex virus-1 selectively targets and treats distant human xenograft tumors that express high MEK activity.
Veerapong J; Bickenbach KA; Shao MY; Smith KD; Posner MC; Roizman B; Weichselbaum RR
Cancer Res; 2007 Sep; 67(17):8301-6. PubMed ID: 17804745
[TBL] [Abstract][Full Text] [Related]
27. Effect of hexamethylene bisacetamide and cyclosporin A on recovery of herpes simplex virus type 2 from the in vitro model of latency in a human neuroblastoma cell line.
Kondo Y; Yura Y; Iga H; Yanagawa T; Yoshida H; Furumoto N; Sato M
Cancer Res; 1990 Dec; 50(24):7852-7. PubMed ID: 2174735
[TBL] [Abstract][Full Text] [Related]
28. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.
Hu ZB; Wu CT; Wang H; Zhang QW; Wang L; Wang RL; Lu ZZ; Wang LS
Cancer Gene Ther; 2008 Mar; 15(3):173-82. PubMed ID: 18157145
[TBL] [Abstract][Full Text] [Related]
29. Enhanced antitumor efficacy of a herpes simplex virus mutant isolated by genetic selection in cancer cells.
Taneja S; MacGregor J; Markus S; Ha S; Mohr I
Proc Natl Acad Sci U S A; 2001 Jul; 98(15):8804-8. PubMed ID: 11438715
[TBL] [Abstract][Full Text] [Related]
30. A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo.
Li B; Liu X; Fan J; Qi R; Bo L; Gu J; Qian Q; Qian C; Liu X
J Gene Med; 2006 Oct; 8(10):1232-42. PubMed ID: 16900558
[TBL] [Abstract][Full Text] [Related]
31. [Cytotoxic effect of oncolytic virus combined with mitomycin against human bladder cancer cells in vitro and in vivo].
Zhao GZ; Tan WL; Zheng SB; Wu YD; Xie Y; Zhu WH
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Nov; 26(11):1623-5, 1628. PubMed ID: 17121717
[TBL] [Abstract][Full Text] [Related]
32. Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus.
Zhang Q; Chen G; Peng L; Wang X; Yang Y; Liu C; Shi W; Su C; Wu H; Liu X; Wu M; Qian Q
Clin Cancer Res; 2006 Nov; 12(21):6523-31. PubMed ID: 17085667
[TBL] [Abstract][Full Text] [Related]
33. Enhanced antiglioma activity of chimeric HCMV/HSV-1 oncolytic viruses.
Shah AC; Parker JN; Gillespie GY; Lakeman FD; Meleth S; Markert JM; Cassady KA
Gene Ther; 2007 Jul; 14(13):1045-54. PubMed ID: 17429445
[TBL] [Abstract][Full Text] [Related]
34. Ultrasound as a method to enhance antitumor ability of oncolytic herpes simplex virus for head and neck cancer.
Okunaga S; Takasu A; Meshii N; Imai T; Hamada M; Iwai S; Yura Y
Cancer Gene Ther; 2015 Apr; 22(3):163-8. PubMed ID: 25656776
[TBL] [Abstract][Full Text] [Related]
35. Combination of measles virus virotherapy and radiation therapy has synergistic activity in the treatment of glioblastoma multiforme.
Liu C; Sarkaria JN; Petell CA; Paraskevakou G; Zollman PJ; Schroeder M; Carlson B; Decker PA; Wu W; James CD; Russell SJ; Galanis E
Clin Cancer Res; 2007 Dec; 13(23):7155-65. PubMed ID: 18056196
[TBL] [Abstract][Full Text] [Related]
36. Cepharanthine exerts antitumor activity on oral squamous cell carcinoma cell lines by induction of p27Kip1.
Harada K; Supriatno ; Yamamoto S; Kawaguchi S; Yoshida H; Sato M
Anticancer Res; 2003; 23(2B):1441-8. PubMed ID: 12820407
[TBL] [Abstract][Full Text] [Related]
37. Potential for efficacy of the oncolytic Herpes simplex virus 1716 in patients with oral squamous cell carcinoma.
Mace AT; Ganly I; Soutar DS; Brown SM
Head Neck; 2008 Aug; 30(8):1045-51. PubMed ID: 18615711
[TBL] [Abstract][Full Text] [Related]
38. A novel fusogenic herpes simplex virus for oncolytic virotherapy of squamous cell carcinoma.
Takaoka H; Takahashi G; Ogawa F; Imai T; Iwai S; Yura Y
Virol J; 2011 Jun; 8():294. PubMed ID: 21663640
[TBL] [Abstract][Full Text] [Related]
39. Virotherapy with a type 2 herpes simplex virus-derived oncolytic virus induces potent antitumor immunity against neuroblastoma.
Li H; Dutuor A; Tao L; Fu X; Zhang X
Clin Cancer Res; 2007 Jan; 13(1):316-22. PubMed ID: 17200370
[TBL] [Abstract][Full Text] [Related]
40. Oncolytic virotherapy for malignant melanoma with herpes simplex virus type 1 mutant HF10.
Watanabe D; Goshima F; Mori I; Tamada Y; Matsumoto Y; Nishiyama Y
J Dermatol Sci; 2008 Jun; 50(3):185-96. PubMed ID: 18226503
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
